Inventor · disambiguated record
Ann-Marie Campbell
Also filed as: CAMPBELL ANN-MARIE
59 granted patents·15 pending applications·751 citations·filing 1998–2023
99Inventor score
Files withFORMA THERAPEUTICS INC35BAYER PHARMACEUTICALS CORP9VALO EARLY DISCOVERY INC8FORMA TM2 INC7BAYER HEALTHCARE LLC3
Top patents by PatentIndex Score
74 records- 0198US10550098B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·17 cites·25 claims
- 0298US10414752B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·19 cites·20 claims
- 0398US9834539B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Dec 5, 2017·28 cites·108 claims
- 0498US9624175B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·25 cites·39 claims
- 0598US9624216B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·26 cites·74 claims
- 0697US11498913B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Nov 15, 2022·4 cites·18 claims
- 0797US9840491B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Dec 12, 2017·22 cites·17 claims
- 0897US9771349B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·27 cites·68 claims
- 0996US10377767B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·16 cites·16 claims
- 1096US10377773B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·18 cites·16 claims
- 1196US10005734B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 26, 2018·25 cites·75 claims
- 1296US10000495B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 19, 2018·21 cites·16 claims
- 1396US9938300B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 10, 2018·23 cites·15 claims
- 1496US9932351B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·24 cites·12 claims
- 1596US9902728B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Feb 27, 2018·24 cites·40 claims
- 1696US9815817B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Nov 14, 2017·24 cites·48 claims
- 1795US10934299B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Mar 2, 2021·7 cites·20 claims
- 1895US10889567B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Jan 12, 2021·5 cites·21 claims
- 1995US10377760B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·17 cites·20 claims
- 2095US10351571B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jul 16, 2019·15 cites·17 claims
- 2195US10280150B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2017·Granted May 7, 2019·19 cites·2 claims
- 2295US10266495B2Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 23, 2019·19 cites·9 claims
- 2395US10253015B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 9, 2019·20 cites·12 claims
- 2494US10519129B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·21 claims
- 2594US10519127B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·24 claims
- 2694US10519130B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·21 claims
- 2794US10519128B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·19 claims
- 2894US10513507B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·9 cites·20 claims
- 2994US10513508B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·8 cites·30 claims
- 3094US10508098B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2019·8 cites·20 claims
- 3194US10294206B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2015·Granted May 21, 2019·7 cites·16 claims
- 3293US10906916B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Feb 2, 2021·4 cites·16 claims
- 3393US6787651B2Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-γ binding agentsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Sep 7, 2004·72 cites·14 claims
- 3492US10577329B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Mar 3, 2020·4 cites·20 claims
- 3592US7517874B2Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of painCARA THERAPEUTICS INC·Filed 2008·Granted Apr 14, 2009·42 cites·20 claims
- 3691US10407419B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 10, 2019·5 cites·5 claims
- 3788US10836741B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 17, 2020·3 cites·28 claims
- 3888US10550099B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·4 cites·15 claims
- 3987US12275715B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Granted Apr 15, 2025·0 cites·23 claims
- 4087US10927130B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Feb 23, 2021·4 cites·16 claims
- 4187US10807976B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·2 cites·18 claims
- 4287US8466283B2Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisHENTEMANN MARTIN·Filed 2007·Granted Jun 18, 2013·19 cites·47 claims
- 4386USRE46856ESubstituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER IP GMBH·Filed 2007·Granted May 22, 2018·9 cites·57 claims
- 4486US7091228B2Preparation and use of aryl alkyl acid derivatives for the treatment of obesityBAYER PHARMACEUTICALS CORP·Filed 2004·Granted Aug 15, 2006·18 cites·20 claims
- 4586US6660752B22,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonistsBAYER PHARMACEUTICALS CORP·Filed 2002·Granted Dec 9, 2003·24 cites·30 claims
- 4685US10981915B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 20, 2021·3 cites·12 claims
- 4783US2023125739A1Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4879US7968576B2Preparation and use of aryl alkyl acid derivatives for the treatment of obesitySMITH ROGER A·Filed 2008·Granted Jun 28, 2011·3 cites·15 claims
- 4976US11739071B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2020·Granted Aug 29, 2023·0 cites·20 claims
- 5074US7423156B2Preparation and use of aryl alkyl acid derivatives for the treatment of obesityBAYER PHARMACEUTICALS CORP·Filed 2006·Granted Sep 9, 2008·1 cites·20 claims
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ann-Marie Campbell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →